Thiazolidinediones, peroxisome proliferator-activated receptor γ agonists, regulate endothelial cell growth and secretion of vasoactive peptides

Yasutomo Fukunaga, Hiroshi Itoh, Kentaro Doi, Tokuji Tanaka, Jun Yamashita, Tae Hwa Chun, Mayumi Inoue, Ken Masatsugu, Naoki Sawada, Takatoshi Saito, Kiminori Hosoda, Hyun Kook, Makiko Ueda, Kazuwa Nakao

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Insulin resistance has been highlighted as a common causal factor for glucose intolerance, hypertension and dyslipidemia, all of which are cardiovascular risk factors. A new class of antidiabetic agents, thiazolidinediones (TZDs), has been developed and demonstrated to improve insulin sensitivity. TZDs are high affinity ligands for peroxisome proliferator-activated receptor γ (PPARγ), the crucial transcription factor for adipocytes. Recent studies showed that PPARγ is also expressed in monocytes/macrophages and is suggested to be involved in atherosclerosis. We could detect PPARγ gene transcript in several cultured endothelial cells (human aortic endothelial cells (HAoECs), human coronary artery endothelial cells (HCAECs), human umbilical vein endothelial cells (HUVECs) and bovine carotid artery endothelial cells (BAECs)) as well as human coronary arteries we examined. Since endothelial dysfunction is critical for atherosclerosis, we investigated the effects of TZDs, troglitazone (TRO) and pioglitazone (PIO), on endothelial cell growth and secretion of C-type natriuretic peptide (CNP), which we demonstrated as a novel endothelium-derived relaxing peptide, and endothelin (ET), a potent vasoconstrictor, using HAoECs, HCAECs, HUVECs and BAECs. When all these cultured endothelial cells were daily treated with TRO and PIO for 5 days, both TRO and PIO (10-8 M) significantly stimulated 3H-thymidine incorporation of all these endothelial cells. In contrast, higher dose of TRO and PIO (10-5 M) significantly suppressed DNA synthesis. TRO and PIO also exerted the compatible effect on the increase of cell numbers. TRO and PIO significantly enhanced CNP secretion from BAECs. In contrast, ET secretion from BAECs was suppressed by both TRO and PIO in a dose-dependent manner. The results of the present study suggest that TZDs modulate endothelial functions, including regulation of endothelial cell growth and secretion of endothelium-derived vasoactive substances, which affect vascular tone and remodeling in the process of atherosclerosis.

Original languageEnglish
Pages (from-to)113-119
Number of pages7
JournalAtherosclerosis
Volume158
Issue number1
DOIs
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Thiazolidinediones
pioglitazone
Peroxisome Proliferator-Activated Receptors
troglitazone
Endothelial Cells
Peptides
Growth
Carotid Arteries
C-Type Natriuretic Peptide
Atherosclerosis
Coronary Vessels
Endothelins
Human Umbilical Vein Endothelial Cells
Endothelium
Insulin Resistance
Cultured Cells
Glucose Intolerance
Vasoconstrictor Agents
Dyslipidemias
Hypoglycemic Agents

Keywords

  • C-type natriuretic peptide
  • Endothelial cells
  • Endothelin
  • Growth
  • Insulin resistance
  • Peroxisome proliferator-activated receptor
  • Thiazolidinediones

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Thiazolidinediones, peroxisome proliferator-activated receptor γ agonists, regulate endothelial cell growth and secretion of vasoactive peptides. / Fukunaga, Yasutomo; Itoh, Hiroshi; Doi, Kentaro; Tanaka, Tokuji; Yamashita, Jun; Chun, Tae Hwa; Inoue, Mayumi; Masatsugu, Ken; Sawada, Naoki; Saito, Takatoshi; Hosoda, Kiminori; Kook, Hyun; Ueda, Makiko; Nakao, Kazuwa.

In: Atherosclerosis, Vol. 158, No. 1, 2001, p. 113-119.

Research output: Contribution to journalArticle

Fukunaga, Y, Itoh, H, Doi, K, Tanaka, T, Yamashita, J, Chun, TH, Inoue, M, Masatsugu, K, Sawada, N, Saito, T, Hosoda, K, Kook, H, Ueda, M & Nakao, K 2001, 'Thiazolidinediones, peroxisome proliferator-activated receptor γ agonists, regulate endothelial cell growth and secretion of vasoactive peptides', Atherosclerosis, vol. 158, no. 1, pp. 113-119. https://doi.org/10.1016/S0021-9150(01)00430-0
Fukunaga, Yasutomo ; Itoh, Hiroshi ; Doi, Kentaro ; Tanaka, Tokuji ; Yamashita, Jun ; Chun, Tae Hwa ; Inoue, Mayumi ; Masatsugu, Ken ; Sawada, Naoki ; Saito, Takatoshi ; Hosoda, Kiminori ; Kook, Hyun ; Ueda, Makiko ; Nakao, Kazuwa. / Thiazolidinediones, peroxisome proliferator-activated receptor γ agonists, regulate endothelial cell growth and secretion of vasoactive peptides. In: Atherosclerosis. 2001 ; Vol. 158, No. 1. pp. 113-119.
@article{31f0f363474644c49eae08394e130794,
title = "Thiazolidinediones, peroxisome proliferator-activated receptor γ agonists, regulate endothelial cell growth and secretion of vasoactive peptides",
abstract = "Insulin resistance has been highlighted as a common causal factor for glucose intolerance, hypertension and dyslipidemia, all of which are cardiovascular risk factors. A new class of antidiabetic agents, thiazolidinediones (TZDs), has been developed and demonstrated to improve insulin sensitivity. TZDs are high affinity ligands for peroxisome proliferator-activated receptor γ (PPARγ), the crucial transcription factor for adipocytes. Recent studies showed that PPARγ is also expressed in monocytes/macrophages and is suggested to be involved in atherosclerosis. We could detect PPARγ gene transcript in several cultured endothelial cells (human aortic endothelial cells (HAoECs), human coronary artery endothelial cells (HCAECs), human umbilical vein endothelial cells (HUVECs) and bovine carotid artery endothelial cells (BAECs)) as well as human coronary arteries we examined. Since endothelial dysfunction is critical for atherosclerosis, we investigated the effects of TZDs, troglitazone (TRO) and pioglitazone (PIO), on endothelial cell growth and secretion of C-type natriuretic peptide (CNP), which we demonstrated as a novel endothelium-derived relaxing peptide, and endothelin (ET), a potent vasoconstrictor, using HAoECs, HCAECs, HUVECs and BAECs. When all these cultured endothelial cells were daily treated with TRO and PIO for 5 days, both TRO and PIO (10-8 M) significantly stimulated 3H-thymidine incorporation of all these endothelial cells. In contrast, higher dose of TRO and PIO (10-5 M) significantly suppressed DNA synthesis. TRO and PIO also exerted the compatible effect on the increase of cell numbers. TRO and PIO significantly enhanced CNP secretion from BAECs. In contrast, ET secretion from BAECs was suppressed by both TRO and PIO in a dose-dependent manner. The results of the present study suggest that TZDs modulate endothelial functions, including regulation of endothelial cell growth and secretion of endothelium-derived vasoactive substances, which affect vascular tone and remodeling in the process of atherosclerosis.",
keywords = "C-type natriuretic peptide, Endothelial cells, Endothelin, Growth, Insulin resistance, Peroxisome proliferator-activated receptor, Thiazolidinediones",
author = "Yasutomo Fukunaga and Hiroshi Itoh and Kentaro Doi and Tokuji Tanaka and Jun Yamashita and Chun, {Tae Hwa} and Mayumi Inoue and Ken Masatsugu and Naoki Sawada and Takatoshi Saito and Kiminori Hosoda and Hyun Kook and Makiko Ueda and Kazuwa Nakao",
year = "2001",
doi = "10.1016/S0021-9150(01)00430-0",
language = "English",
volume = "158",
pages = "113--119",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Thiazolidinediones, peroxisome proliferator-activated receptor γ agonists, regulate endothelial cell growth and secretion of vasoactive peptides

AU - Fukunaga, Yasutomo

AU - Itoh, Hiroshi

AU - Doi, Kentaro

AU - Tanaka, Tokuji

AU - Yamashita, Jun

AU - Chun, Tae Hwa

AU - Inoue, Mayumi

AU - Masatsugu, Ken

AU - Sawada, Naoki

AU - Saito, Takatoshi

AU - Hosoda, Kiminori

AU - Kook, Hyun

AU - Ueda, Makiko

AU - Nakao, Kazuwa

PY - 2001

Y1 - 2001

N2 - Insulin resistance has been highlighted as a common causal factor for glucose intolerance, hypertension and dyslipidemia, all of which are cardiovascular risk factors. A new class of antidiabetic agents, thiazolidinediones (TZDs), has been developed and demonstrated to improve insulin sensitivity. TZDs are high affinity ligands for peroxisome proliferator-activated receptor γ (PPARγ), the crucial transcription factor for adipocytes. Recent studies showed that PPARγ is also expressed in monocytes/macrophages and is suggested to be involved in atherosclerosis. We could detect PPARγ gene transcript in several cultured endothelial cells (human aortic endothelial cells (HAoECs), human coronary artery endothelial cells (HCAECs), human umbilical vein endothelial cells (HUVECs) and bovine carotid artery endothelial cells (BAECs)) as well as human coronary arteries we examined. Since endothelial dysfunction is critical for atherosclerosis, we investigated the effects of TZDs, troglitazone (TRO) and pioglitazone (PIO), on endothelial cell growth and secretion of C-type natriuretic peptide (CNP), which we demonstrated as a novel endothelium-derived relaxing peptide, and endothelin (ET), a potent vasoconstrictor, using HAoECs, HCAECs, HUVECs and BAECs. When all these cultured endothelial cells were daily treated with TRO and PIO for 5 days, both TRO and PIO (10-8 M) significantly stimulated 3H-thymidine incorporation of all these endothelial cells. In contrast, higher dose of TRO and PIO (10-5 M) significantly suppressed DNA synthesis. TRO and PIO also exerted the compatible effect on the increase of cell numbers. TRO and PIO significantly enhanced CNP secretion from BAECs. In contrast, ET secretion from BAECs was suppressed by both TRO and PIO in a dose-dependent manner. The results of the present study suggest that TZDs modulate endothelial functions, including regulation of endothelial cell growth and secretion of endothelium-derived vasoactive substances, which affect vascular tone and remodeling in the process of atherosclerosis.

AB - Insulin resistance has been highlighted as a common causal factor for glucose intolerance, hypertension and dyslipidemia, all of which are cardiovascular risk factors. A new class of antidiabetic agents, thiazolidinediones (TZDs), has been developed and demonstrated to improve insulin sensitivity. TZDs are high affinity ligands for peroxisome proliferator-activated receptor γ (PPARγ), the crucial transcription factor for adipocytes. Recent studies showed that PPARγ is also expressed in monocytes/macrophages and is suggested to be involved in atherosclerosis. We could detect PPARγ gene transcript in several cultured endothelial cells (human aortic endothelial cells (HAoECs), human coronary artery endothelial cells (HCAECs), human umbilical vein endothelial cells (HUVECs) and bovine carotid artery endothelial cells (BAECs)) as well as human coronary arteries we examined. Since endothelial dysfunction is critical for atherosclerosis, we investigated the effects of TZDs, troglitazone (TRO) and pioglitazone (PIO), on endothelial cell growth and secretion of C-type natriuretic peptide (CNP), which we demonstrated as a novel endothelium-derived relaxing peptide, and endothelin (ET), a potent vasoconstrictor, using HAoECs, HCAECs, HUVECs and BAECs. When all these cultured endothelial cells were daily treated with TRO and PIO for 5 days, both TRO and PIO (10-8 M) significantly stimulated 3H-thymidine incorporation of all these endothelial cells. In contrast, higher dose of TRO and PIO (10-5 M) significantly suppressed DNA synthesis. TRO and PIO also exerted the compatible effect on the increase of cell numbers. TRO and PIO significantly enhanced CNP secretion from BAECs. In contrast, ET secretion from BAECs was suppressed by both TRO and PIO in a dose-dependent manner. The results of the present study suggest that TZDs modulate endothelial functions, including regulation of endothelial cell growth and secretion of endothelium-derived vasoactive substances, which affect vascular tone and remodeling in the process of atherosclerosis.

KW - C-type natriuretic peptide

KW - Endothelial cells

KW - Endothelin

KW - Growth

KW - Insulin resistance

KW - Peroxisome proliferator-activated receptor

KW - Thiazolidinediones

UR - http://www.scopus.com/inward/record.url?scp=0034898803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034898803&partnerID=8YFLogxK

U2 - 10.1016/S0021-9150(01)00430-0

DO - 10.1016/S0021-9150(01)00430-0

M3 - Article

VL - 158

SP - 113

EP - 119

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 1

ER -